

TOUS COBAYES: LA PREUVE

Clinicaltrial.gov, site officiel d'enregistrement des essais cliniques des médicaments dans le monde

Capture d'écran du bas de la page: <https://clinicaltrials.gov/ct2/show/study/NCT04516746>

Study Description

Brief Summary:
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Condition or disease	Intervention/treatment	Phase
COVID-19	Biological: AZD1222	Phase 3
SARS-CoV-2	Biological: Placebo	

Detailed Description:
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

Study Design

Study Type: Interventional (Clinical Trial)
Actual Enrollment: 32459 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are assigned to one of two or more groups in parallel for the duration of the study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double Blind: two or more parties are unaware of the intervention assignment.
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Actual Study Start Date: August 28, 2020
Actual Primary Completion Date: March 5, 2021
Estimated Study Completion Date: February 14, 2023

Arms and Interventions

Fin de la phase 3 le 14 février 2023 de l'essai randomisé de l'AZD1222 «vaccin» d'Astrazeneca pour la prévention du COVID-19

LES COVAX-19 BLESSENT ET TUENT DEJA

Au 22 mai 2021, 1 196 190 blessés et 12 184 morts dus aux vaccins covid-19 enregistrés en Europe sur:

EudraVigilance - European database of suspected adverse drug reaction reports

The European Medicines Agency publishes these data so that its stakeholders, including the general public, can access information that European regulatory authorities use to review the safety of a medicine or active substance. **Transparency** is a key guiding principle of the Agency.

COVID-19 Vaccine Adverse Drug Reactions
12,184 DEAD
1,196,190 Injuries Through May 22, 2021

- COVID-19 MRNA VACCINE MODERNA (CX-024414)
- COVID-19 MRNA VACCINE PFIZER-BIONTECH
- COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)
- COVID-19 VACCINE JANSSEN (AD26.COV2.S)

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EudraVigilance

Rapports de surveillance des médicaments par EUDRAVIGILANCE sur:
<https://www.adrreports.eu/fr/> ou sur: <https://dap.ema.europa.eu/analytics/saw.dll?bieehome&startPage=1>

**TOUS LES EFFETS INDESIRABLES NE SONT PAS DÉCLARÉS NI ENREGISTRÉS
RENSEIGNEZ-VOUS !**